BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 33439725)

  • 1. Machine Learning Frameworks to Predict Neoadjuvant Chemotherapy Response in Breast Cancer Using Clinical and Pathological Features.
    Meti N; Saednia K; Lagree A; Tabbarah S; Mohebpour M; Kiss A; Lu FI; Slodkowska E; Gandhi S; Jerzak KJ; Fleshner L; Law E; Sadeghi-Naini A; Tran WT
    JCO Clin Cancer Inform; 2021 Jan; 5():66-80. PubMed ID: 33439725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of pathologic complete response to neoadjuvant chemotherapy using machine learning models in patients with breast cancer.
    Kim JY; Jeon E; Kwon S; Jung H; Joo S; Park Y; Lee SK; Lee JE; Nam SJ; Cho EY; Park YH; Ahn JS; Im YH
    Breast Cancer Res Treat; 2021 Oct; 189(3):747-757. PubMed ID: 34224056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Machine Learning With Multiparametric Magnetic Resonance Imaging of the Breast for Early Prediction of Response to Neoadjuvant Chemotherapy and Survival Outcomes in Breast Cancer Patients.
    Tahmassebi A; Wengert GJ; Helbich TH; Bago-Horvath Z; Alaei S; Bartsch R; Dubsky P; Baltzer P; Clauser P; Kapetas P; Morris EA; Meyer-Baese A; Pinker K
    Invest Radiol; 2019 Feb; 54(2):110-117. PubMed ID: 30358693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Texture analysis using machine learning-based 3-T magnetic resonance imaging for predicting recurrence in breast cancer patients treated with neoadjuvant chemotherapy.
    Eun NL; Kang D; Son EJ; Youk JH; Kim JA; Gweon HM
    Eur Radiol; 2021 Sep; 31(9):6916-6928. PubMed ID: 33693994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Machine learning prediction of pathological complete response and overall survival of breast cancer patients in an underserved inner-city population.
    Dell'Aquila K; Vadlamani A; Maldjian T; Fineberg S; Eligulashvili A; Chung J; Adam R; Hodges L; Hou W; Makower D; Duong TQ
    Breast Cancer Res; 2024 Jan; 26(1):7. PubMed ID: 38200586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative digital histopathology and machine learning to predict pathological complete response to chemotherapy in breast cancer patients using pre-treatment tumor biopsies.
    Saednia K; Lagree A; Alera MA; Fleshner L; Shiner A; Law E; Law B; Dodington DW; Lu FI; Tran WT; Sadeghi-Naini A
    Sci Rep; 2022 Jun; 12(1):9690. PubMed ID: 35690630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intratumoral and peritumoral radiomics for the pretreatment prediction of pathological complete response to neoadjuvant chemotherapy based on breast DCE-MRI.
    Braman NM; Etesami M; Prasanna P; Dubchuk C; Gilmore H; Tiwari P; Plecha D; Madabhushi A
    Breast Cancer Res; 2017 May; 19(1):57. PubMed ID: 28521821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring the added value of pretherapeutic MR descriptors in predicting breast cancer pathologic complete response to neoadjuvant chemotherapy.
    Malhaire C; Selhane F; Saint-Martin MJ; Cockenpot V; Akl P; Laas E; Bellesoeur A; Ala Eddine C; Bereby-Kahane M; Manceau J; Sebbag-Sfez D; Pierga JY; Reyal F; Vincent-Salomon A; Brisse H; Frouin F
    Eur Radiol; 2023 Nov; 33(11):8142-8154. PubMed ID: 37318605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MRI-based machine learning radiomics can predict HER2 expression level and pathologic response after neoadjuvant therapy in HER2 overexpressing breast cancer.
    Bitencourt AGV; Gibbs P; Rossi Saccarelli C; Daimiel I; Lo Gullo R; Fox MJ; Thakur S; Pinker K; Morris EA; Morrow M; Jochelson MS
    EBioMedicine; 2020 Nov; 61():103042. PubMed ID: 33039708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complete Metabolic Response on Interim
    Chen S; Ibrahim NK; Yan Y; Wong ST; Wang H; Wong FC
    Oncologist; 2017 May; 22(5):526-534. PubMed ID: 28377466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ultrasound deep learning radiomics and clinical machine learning models to predict low nuclear grade, ER, PR, and HER2 receptor status in pure ductal carcinoma
    Zhu M; Kuang Y; Jiang Z; Liu J; Zhang H; Zhao H; Luo H; Chen Y; Peng Y
    Gland Surg; 2024 Apr; 13(4):512-527. PubMed ID: 38720675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and validation of a prognostic model for HER2-low breast cancer to evaluate neoadjuvant therapy.
    Li X; Lin Z; Yu Q; Qiu C; Lai C; Huang H; Zhang Y; Zhang W; Zhu J; Huang X; Li W
    Gland Surg; 2023 Feb; 12(2):183-196. PubMed ID: 36915818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Digital image analysis and machine learning-assisted prediction of neoadjuvant chemotherapy response in triple-negative breast cancer.
    Fisher TB; Saini G; Rekha TS; Krishnamurthy J; Bhattarai S; Callagy G; Webber M; Janssen EAM; Kong J; Aneja R
    Breast Cancer Res; 2024 Jan; 26(1):12. PubMed ID: 38238771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Texture Analysis with 3.0-T MRI for Association of Response to Neoadjuvant Chemotherapy in Breast Cancer.
    Eun NL; Kang D; Son EJ; Park JS; Youk JH; Kim JA; Gweon HM
    Radiology; 2020 Jan; 294(1):31-41. PubMed ID: 31769740
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Li P; Wang X; Xu C; Liu C; Zheng C; Fulham MJ; Feng D; Wang L; Song S; Huang G
    Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1116-1126. PubMed ID: 31982990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction model of the response to neoadjuvant chemotherapy in breast cancers by a Naive Bayes algorithm.
    Yang L; Fu B; Li Y; Liu Y; Huang W; Feng S; Xiao L; Sun L; Deng L; Zheng X; Ye F; Bu H
    Comput Methods Programs Biomed; 2020 Aug; 192():105458. PubMed ID: 32302875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A nomogram to predict pathologic complete response (pCR) and the value of tumor-infiltrating lymphocytes (TILs) for prediction of response to neoadjuvant chemotherapy (NAC) in breast cancer patients.
    Hwang HW; Jung H; Hyeon J; Park YH; Ahn JS; Im YH; Nam SJ; Kim SW; Lee JE; Yu JH; Lee SK; Choi M; Cho SY; Cho EY
    Breast Cancer Res Treat; 2019 Jan; 173(2):255-266. PubMed ID: 30324273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum Tumor Marker Levels might have Little Significance in Evaluating Neoadjuvant Treatment Response in Locally Advanced Breast Cancer.
    Wang YJ; Huang XY; Mo M; Li JW; Jia XQ; Shao ZM; Shen ZZ; Wu J; Liu GY
    Asian Pac J Cancer Prev; 2015; 16(11):4603-8. PubMed ID: 26107211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multivariate machine learning models for prediction of pathologic response to neoadjuvant therapy in breast cancer using MRI features: a study using an independent validation set.
    Cain EH; Saha A; Harowicz MR; Marks JR; Marcom PK; Mazurowski MA
    Breast Cancer Res Treat; 2019 Jan; 173(2):455-463. PubMed ID: 30328048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discrepancies Between Pathological Tumor Responses and Estimations of Complete Response by Magnetic Resonance Imaging After Neoadjuvant Chemotherapy Differ by Breast Cancer Subtype.
    Namura M; Tsunoda H; Yagata H; Hayashi N; Yoshida A; Morishita E; Takei J; Suzuki K; Yamauchi H
    Clin Breast Cancer; 2018 Apr; 18(2):128-134. PubMed ID: 28843513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.